Clinical Practice and Targeted Therapies in Personalized Medicine Welcome to 5 th Munich Biomarker Conference December 1 st 2 nd, 2015 RAMADA Hotel & Conference Center München Messe
We thank our sponsors
We thank our sponsors
Bavaria: from tradition
to innovation
There are more than 345 biotech and pharma companies in Bavaria More than 345 biotech & pharma companies, of which 170 are SME 7 approved drugs from German biotechnology companies on the global market 40,000 employees in biotech & pharma & academia 8.3 billion in revenues p.a., 580 mio. from biotech-sme > 3.5 billion invested in biotech since 1995 6
With 30,000 employees working in the industry, Bavaria is a top European biotechnology cluster* Total revenues 30,000 11,500 Bio(tech)/Pharma + 5.6% compared to 2013 Biotechnology (alone) + 4.3% compared to 2013 *Genetic Engineering and Biotechnology News 2015 7
Bavarian biotech SME focus on therapeutics and diagnostics Bavarian Biotech SME - area of work Major indications 61 Biotech Therapeutics & Diagnostics Biotech Devices & Reagents Biotech Agro, Food, Environment 13 54 36 1 Other 2 Autoimmune 3 CNS 49 16 15 13 13 Biotech Bioinformatics Biotech DNA/Protein Analytics 6 3 13 4 Infectiology 5 Oncology 8
Bavaria s drug development pipeline is filled with 65 drug candidates in clinical development Marketed Drugs (derived from SME) Source: Bavarian Biotech Report 2014/15 9
Bavaria provides an excellent academic life science environment with cutting edge research 10
Bio M is the cluster development organization for Munich and Bavaria Würzburg Companies:22 Space: > 4000 sqm Regensburg Companies:44 Space: >18.000 sqm Erlangen Companies:>30 Space: > 5.000 sqm Straubing Companies:9 Space: >1.200 sqm Martinsried Companies: 70 Size: 23.000 sqm Weihenstephan Companies: 7 Space: 2.300 sqm 11
All national health centers are (co)located in Bavaria s capital Munich 12
Bio M and Munich Biotech Cluster at a Glance 13
Bio M accelerating biomedical innovation Professional Biotech Cluster Management since 1997 Bio M is the central point of contact for medical biotechnology in Munich and Bavaria. The major goal of Bio M is to foster the sustainable development of the Munich & Bavarian Biotech Cluster and expand its position as one of the leading life science clusters in Europe. With its outstanding and broad network and services, Bio M is a valuable partner for biotech SME, academia / clinicians, pharma and investors. Bio M is a non-profit organisation and funded by the Bavarian State Ministry of Economic Affairs, Media, Energy and Technology. 14
Bio M accelerating biomedical innovation Central contact point for research, entrepreneurs & companies SME Big Pharma Academia Funding Advices Partnering Business Development Networking Seminars & Workshops Scouting & Incubation Start-up Consulting Information Events Lobbying 15
Bio M serves as an incubator and fosters biomedical innovation Bio M Award Bio M Mentor Circle Bio M Incubation Bio M Pitch Training Bio M BioEntrepreneur Lounge Bio M BioEntrepreneur Bootcamp 16
The Munich Biotech Cluster Success stories founded in 2011 as spin-off of the Technical University of Munich TUM Unique biological format: anticalin therapeutics In April 2011, Pieris signs discovery deal with Daiichi Sankyo worth 207 million In December 2014, Pieris goes public in a reverse merger transaction, NASDAQ listing in 2015 (Pieris Inc.) founded 2005 as a spin-off of the Max Planck Institute for Biochemistry Fc-gamma receptor IIb based protein therapeutics to treat autoimmune diseases and allergies In March 2015, Baxter Bioscience acquires SuppreMol in a transaction value of 200 million founded 2001 as a spin-off of the Max Planck Institute for Biochemistry monoclonal antibodies to treat cancer In May 2008 Daiichi Sankyo acquires U3 Pharma in a cash transaction worth 150 million founded as a spin-off of the LMU Munich in 1996 BiTE antibodies (Bispecific T-cell Engagers) In January 2012, Amgen acquired Micromet in a cash transaction worth $ 1.16 billion 2014: FDA Breakthrough designation for Blinatumomab US approval in late 2014 ( Blincyto ) founded as a spin-off from the universities of Würzburg and Tuebingen in 2006 Cyclopeptide for the treatment of heart insufficiency In June 2012, JANSSEN-CILAG acquired Corimmun in a transaction value of $ 100 million
Leading-Edge Cluster Munich m 4 Personalized Medicine Winner in the national leading edge cluster competition 5 year funding by BMBF In total about 100 mio for Personalized Medicine (2010-2015) 50 research projects + 6 structural projects >100 partners involved Vision for 2020: Center of Excellence for Personalized Medicine
Bio M Connecting the Cluster Partners
50 R&D Projects along the Value Chain Biotech SME Pharma industry Academia Clinics Research Preclinic Clinical phases I - III Approval Market Biomarker identification & validation Value-added chain in personalized medicine Test development Test Kit Approval Market
50 m 4 R&D-Projects 21 preclinical development projects of new therapeutics 5 clinical trials 11 diagnostic R&D projects 13 biomarker identification projects U3 Pharma Indications: oncology (17) autoimmune diseases (5) cardiovascular diseases (2) neurological diseases (3) infectious diseases (3) Schimpf, RCI 4SC AG
Bio M recognizes the challenges of the medicine of the future and supports its development by identifying and connecting the appropriate partners from science, industry, medicine and finance. Bio M accompanies the innovation process by developing and providing target-oriented measures and custom-fit instruments. our action and tool for you: the Munich Biomarker Conference! Bio M Biotech Cluster Development GmbH Am Klopferspitz 19 a I 82152 Martinsried-Munich I Germany Phone.: +49 (0)89 899679-0 I Fax: +49 (0)89 899679-79 Email: info@bio-m.org
Exhibitor List Abcam plc Agilent Technologies Affymetrix Austrian Institute of Technology (AIT) Bavarian Research Alliance (BayFor) BioM Biotech Cluster Development Biobank der Blutspender BIOCRATES Life Sciences BioPark Regensburg Bio-Rad Laboratories BioSysNet Cryoshop FibroTx ForBiMed Forschungsverbund Formulatrix Hamilton Robotics Innovations und Gründerzentrum Würzburg (IGZ) Luminex Merck Millipore Miltenyi Biotec National Biological Service (NBS) Pateris Personalis ProteinSimple RainDance Technologies tebu-bio Tepnel Pharma Services